1. Home
  2. Analysis
  3. Fycompa
  4. Multiple-drug-resistance

Fycompa and Multiple-drug resistance - a phase IV clinical study of FDA data

Summary:

Multiple-drug resistance is reported as a side effect among people who take Fycompa (perampanel), especially for people who are male, 20-29 old, also take Levetiracetam, and have Seizures.

The phase IV clinical study analyzes which people have Multiple-drug resistance when taking Fycompa. It is created by eHealthMe based on reports of 4,363 people who have side effects when taking Fycompa from the FDA, and is updated regularly.

What is Fycompa?

Fycompa has active ingredients of perampanel. eHealthMe is studying from 4,387 Fycompa users. Check the latest studies of Fycompa.

What is Multiple-drug resistance?

Multiple-drug resistance is found to be associated with 245 drugs and 255 conditions by eHealthMe. Check the latest studies of Multiple-drug resistance.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

4,363 people reported to have side effects when taking Fycompa.
Among them, 42 people (0.96%) have Multiple-drug resistance.

Could Fycompa cause Multiple-drug resistance?

Among these 42 people:

What is the gender of people who have Multiple-drug resistance when taking Fycompa? *

  • female: 36.11 %
  • male: 63.89 %

What is the age of people who have Multiple-drug resistance when taking Fycompa? *

  • 0-1: 0.0 %
  • 2-9: 4.17 %
  • 10-19: 8.33 %
  • 20-29: 50.0 %
  • 30-39: 37.5 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

What are other drugs people take besides Fycompa? *

  1. Levetiracetam: 29 people, 69.05%
  2. Clobazam: 25 people, 59.52%
  3. Valproic Acid: 16 people, 38.10%
  4. Vimpat: 14 people, 33.33%
  5. Carbamazepine: 14 people, 33.33%
  6. Lacosamide: 14 people, 33.33%
  7. Topiramate: 14 people, 33.33%
  8. Lamotrigine: 13 people, 30.95%
  9. Tegretol: 13 people, 30.95%
  10. Oxcarbazepine: 10 people, 23.81%

What are other side effects people have besides Multiple-drug resistance? *

  1. Head Injury: 11 people, 26.19%
  2. Drug Hypersensitivity: 10 people, 23.81%
  3. Facial Bones Fracture (bone fracture of face): 10 people, 23.81%
  4. General Physical Health Deterioration (weak health status): 9 people, 21.43%
  5. Partial Seizures (seizures which affect only a part of the brain at onset): 6 people, 14.29%
  6. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 7.14%
  7. Drowsiness: 3 people, 7.14%
  8. Atonic Seizures (minor type of seizure): 3 people, 7.14%
  9. Drug Level Increased: 3 people, 7.14%
  10. Tonic Convulsion (the person will quickly lose consciousness and the skeletal muscles will suddenly tense, often causing the extremities to be pulled towards the body or rigidly pushed away from it): 3 people, 7.14%

What are the existing conditions these people have? *

  1. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 19 people, 45.24%
  2. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 6 people, 14.29%
  3. Anaemia (lack of blood): 3 people, 7.14%
  4. Petit Mal Epilepsy (absence seizure): 2 people, 4.76%
  5. Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 2 people, 4.76%
  6. Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 1 person, 2.38%
  7. Partial Seizures With Secondary Generalisation (partial seizure may spread within the brain, a process known as secondary generalization): 1 person, 2.38%
  8. Juvenile Myoclonic Epilepsy (childhood epilepsy occurring early in morning affecting 12 to 18 years): 1 person, 2.38%
  9. Idiopathic Generalised Epilepsy (epileptic disorders that are believed to have a strong underlying genetic basis): 1 person, 2.38%
  10. General Anaesthesia: 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Fycompa and have Multiple-drug resistance?

- Check whether Multiple-drug resistance is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fycompa:

Multiple-drug resistance treatments and more:

How severe was Multiple-drug resistance and when was it recovered:

Expand to all the drugs that have ingredients of perampanel:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fycompa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple-drug resistance:

Browse all the conditions that are associated with Multiple-drug resistance:

How the study uses the data?

The study uses data from the FDA. It is based on perampanel (the active ingredients of Fycompa) and Fycompa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.